

# Clovis Lusivika-Nzinga

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9315657/publications.pdf>

Version: 2024-02-01

6

papers

35

citations

2258059

3

h-index

2053705

5

g-index

6

all docs

6

docs citations

6

times ranked

100

citing authors

#	ARTICLE	IF	CITATIONS
1	The dynamic effect of direct-acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C. Journal of Viral Hepatitis, 2019, 26, 1489-1492.	2.0	13
2	Predictive factors for hepatocellular carcinoma in chronic hepatitis B using structural equation modeling: a prospective cohort study. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101713.	1.5	10
3	Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis. BMC Infectious Diseases, 2022, 22, 94.	2.9	6
4	Sofosbuvir-Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real-life experience from the HEPATHER ANRS CO22 cohort. Journal of Viral Hepatitis, 2020, 27, 964-973.	2.0	5
5	Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients—authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 53, 1050-1050.	3.7	1
6	Editorial: similar risk of hepatocellular carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir—new clues from Europe. Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 53, 659-659.	3.7	0